J&J Vision announces availability of TECNIS Synergy IOL
Company introduces 'revolutionary' continuous-range-of-vision IOL
Priscilla Lynch
Published: Sunday, September 15, 2019
JOHNSON & Johnson Vision (JJV) invites ESCRS delegates to look at what the company describes as its “revolutionary” continuous-range-of-vision intraocular lens for patients with cataracts, which is now available in Europe, Australia and New Zealand.
“TECNIS Synergy™ IOL creates a new standard in presbyopia-correcting IOL technology, allowing patients to experience continuous high-contrast vision from far through near, even in low-light conditions,” a company spokesperson said.
“With TECNIS Synergy IOL, we have created our most advanced IOL solution yet, which gives patients the clear, continuous range of vision they want, day and night,” said Tom Frinzi, Worldwide President, Surgical, Johnson & Johnson Vision.
“As ophthalmic pioneers, we continue to challenge ourselves on a daily basis to create solutions to the ever-changing needs of patients. Today, we stay true to our legacy of innovation with the introduction of TECNIS Synergy IOL, which we believe will redefine the industry standard for IOL quality and performance.”
Visit the JJV booth to learn more – Pavilion 7, Floor 7.2 Booth #E112
Tags: intraocular lens
Latest Articles
A New High for Hyperopia
Hyperopia patients can expect a rise in the array of treatments.
Research Committee is Engine Driving the Future of ESCRS
Commitment to evidence-based medicine anchors studies and other projects.
ESCRS EPICAT Study Updates
Early results suggest subconjunctival 10 mg triamcinolone an effective strategy for dropless cataract surgery.
Second Global Consensus on Keratoconus
Forthcoming position paper to provide an updated and expanded view on evaluation and management.
Automating Cataract Surgery Assessment
AI system measures eye stability and centration in procedures.
Post-LASIK Tonometer Takes ESCRS Innovators Den Prize
Good ideas lead to solutions to unmet needs.
ESCRS forms Functional Vision Working Group
Expanding the Limits of KLEx
Hyperopia treatment receives CE approval; mixed astigmatism may follow.